With more than 2,100 hematology and oncology trained staff, PPD provides our clients with dedicated internal resources throughout their studies. Some of our key experts and their insights are highlighted below.
Vice President, Hematology and Oncology, Global Project Management
Alice Donnelly is vice president and therapeutic area head for global project management.
In this role, she serves as global therapeutic head with overall global responsibility for the strategic direction, business operations and operational delivery for all hematology and oncology studies.
Her leadership includes managing a team of directors, associate directors and project managers who are accountable for all project deliverables.
Donnelly joined PPD in 1995 as a clinical research associate (CRA) after a similar role with American Cyanamid in Great Britain. While at PPD, she served as project manager for two registrational trials in HIV/AIDS before leaving the company in 2001 for additional industry experience. She joined Bristol Myers-Squibb as a clinical protocol manager and spent 13 years honing her therapeutic area and leadership expertise through a series of positions with increased levels of responsibility across in-house and outsourced programs and teams. While her therapeutic expertise is greatest in hematology and oncology, she also has clinical research experience in the areas of infectious disease, immunoscience, metabolics and neurology.
Donnelly holds a bachelor’s degree in pharmacology from University College Dublin in Ireland, and a Master of Business Administration from the University of North Carolina Wilmington.
Adaptive trial designs offer the means to make oncology trials more informative and efficient.
Dirk Reitsma, M.D.
Vice President, Global Product Development
Dirk Reitsma, M.D., is vice president and oncology therapeutic area head for global product development.
In this role, he leads the oncology product development strategy team and provides clinical trial design guidance to clients in this therapeutic category. In addition, he established and leads the company’s biosimilar services development group, which brings together cross-functional, global expertise and resources in the development of large molecule biologic drugs.
Dr. Reitsma has extensive clinical development experience, having joined PPD in 2010 from MedImmune, where he served as vice president of clinical development since 2004. At MedImmune, he led the company’s active clinical oncology programs in biologics, and oversaw the expansion of its oncology clinical development department. Dr. Reitsma’s experience also includes serving as vice president of clinical affairs and medical director at Antigenics, and as associate director and senior clinical research physician in oncology at Novartis Pharmaceuticals.
Earlier in his career, he was associate director, clinical research head, clinical section, at Bionetics Research, Inc., and medical advisor in the medical research department at Organon International, Inc. in Rotterdam, The Netherlands. Dr. Reitsma received a bachelor’s degree in science from the Medical Faculty of Rotterdam and a medical degree from Erasmus University in The Netherlands.
PPD was selected to conduct central study activities for a Phase I/II pediatric leukemia study that evaluated study drug.